Recon: Patients, providers left with questions on FDA’s breakthrough devices; BMS, Nektar end $3.6B deal after latest late-stage misses
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy